Navigation Links
Press statement on new CDC MMWR on Klebseilla pneumonia Carbapenemase-producing organisms
Date:3/18/2009

The Centers for Disease Control and Prevention (CDC) today released new infection control recommendations on Klebseilla pneumoniae Carbapenemase (KPC)-Producing Organisms, one of the most treatment-resistant gram-negative bacterium. Recent studies have shown that infections with these highly resistant bacteria are a growing problem in health care settings. In Guidance for Control of Infections with Carbapenem-Resistant or Carbapenemase-Producing Enterobacteriaceae in Acute Care Facilities published in the MMWR, CDC recommends an aggressive infection control approach to limit the emergence of these organisms.

Below Are Quotes from Mark Rupp, MD, President of SHEA

"The new guidelines highlight the need to educate clinicians and public health professionals about the importance of screening for Klebsiella pneuomoniae Carbapenemase (KPC)-Producing Organisms. If hospitals follow the CDC guidelines to detect and identify Klebsiella and Carbapenemase, then we can potentially halt the transmission of a highly treatment-resistant Gram-negative organism and prevent a large scale public health problem.

While KPC is still rare and occurs only sporadically in most parts of the country, an aggressive infection control approach needs to be taken now. These new guidelines suggest that facilities start by checking microbioloigy results for the last six to twelve months. Facilities finding evidence of these organisms should conduct a focused risk assessment or examine high-risk wards including intensive care units to make sure there is no evidence of ongoing transmission. The strategy for testing uses a selection process to get rid of most other organisms and focuses on the ones that are likely to be treatment-resistant including Carbapenem resistant Klebsiella.

For example, Israel has had widespread public health problems with these organisms, yet has managed to contain them in a short time period by implementing targeted screening and prevention practices.

The focused screening is important because there is a need to be both proactive in preventing the spread of KPCs yet judicious and mindful of limited hospital resources."


'/>"/>

Contact: Sharon Reis
sreis@gymr.com
202-745-5103
Society for Healthcare Epidemiology of America
Source:Eurekalert

Related biology news :

1. Regulatory molecule for tumor formation or suppression identified by Singapore, US researchers
2. American Chemical Societys weekly PressPac -- March 11, 2009
3. New tracking tags are providing fish-eye views of ways to manage depressed fisheries
4. Is it really only our kidneys that control blood pressure?
5. Researchers take first look at the genetic dynamics of inbreeding depression
6. Study suggests salt might be natures antidepressant
7. Children seriously affected when a parent suffers from depression
8. Chantix side effects no worse with depression history
9. Suppressing cancer with a master control gene
10. Press statement on new CDC MRSA study from SHEA president
11. Molecule that suppresses immune response under study in type 1 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... 27, 2016 , ... Newly created 4Sight Medical Solutions ... the healthcare market. The company's primary focus is on new product introductions, to ... that are necessary to help companies efficiently bring their products to market. , ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
Breaking Biology Technology: